Roth Capital Predicts Cingulate’s Q1 Earnings (NASDAQ:CING)

Cingulate Inc. (NASDAQ:CING) – Research analysts at Roth Capital upped their Q1 2025 earnings estimates for Cingulate in a report released on Monday, March 31st. Roth Capital analyst B. Pachaiyappan now forecasts that the company will earn ($0.96) per share for the quarter, up from their prior estimate of ($2.19). Roth Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Cingulate’s current full-year earnings is ($11.69) per share. Roth Capital also issued estimates for Cingulate’s Q2 2025 earnings at ($0.72) EPS, Q3 2025 earnings at ($0.63) EPS, Q4 2025 earnings at ($0.37) EPS, FY2025 earnings at ($2.68) EPS and FY2026 earnings at ($2.48) EPS.

Other equities analysts have also recently issued research reports about the company. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Cingulate in a report on Thursday, March 6th. Roth Mkm initiated coverage on Cingulate in a research note on Friday, January 10th. They set a “buy” rating and a $12.00 target price for the company.

Cingulate Stock Performance

Shares of Cingulate stock opened at $4.11 on Wednesday. Cingulate has a fifty-two week low of $1.80 and a fifty-two week high of $20.83. The company has a market cap of $13.20 million, a P/E ratio of -0.28 and a beta of -0.83. The firm has a 50-day simple moving average of $4.22 and a two-hundred day simple moving average of $4.43.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Commonwealth Equity Services LLC boosted its holdings in Cingulate by 281.5% in the 4th quarter. Commonwealth Equity Services LLC now owns 43,022 shares of the company’s stock worth $212,000 after buying an additional 31,746 shares during the last quarter. Geode Capital Management LLC acquired a new stake in shares of Cingulate in the fourth quarter worth approximately $135,000. Jane Street Group LLC acquired a new stake in shares of Cingulate in the third quarter worth approximately $106,000. Finally, AlphaMark Advisors LLC raised its stake in Cingulate by 50,000.0% in the 4th quarter. AlphaMark Advisors LLC now owns 5,010 shares of the company’s stock valued at $25,000 after purchasing an additional 5,000 shares during the last quarter. Institutional investors and hedge funds own 41.31% of the company’s stock.

About Cingulate

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.